Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

被引：6
|
作者：
Kirby, Roger S. [1 ]
Carson, Culley, III [3 ]
Dasgupta, Prokar [1 ,2 ]
机构：
[1] Kings Coll London, Guys Hosp, Prostate Ctr, London WC2R 2LS, England
[2] Kings Coll London, Guys Hosp, Dept Urol, London WC2R 2LS, England
[3] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷 / 05期
关键词：
treatment for prostatitis; tadalafil; 5; mg; pelvic pain; prostatitis; ERECTILE DYSFUNCTION; TADALAFIL; PROSTATITIS; MECHANISM; SYMPTOMS; LUTS; BPH;
D O I：
10.1111/bju.12681
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 695
页数：2
相关论文
共 50 条
  • [1] Treatment of Chronic Prostatitis with Phosphodiesterase Type 5 Inhibitors
    Alzahrani, M. A.
    Binsaleh, S.
    Safar, O.
    Almurayyi, M.
    Aboukhshaba, A.
    Hakami, B. O.
    Albarman, S.
    Alfakhri, A.
    Almannie, R.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 : 67 - 78
  • [2] Treatment Satisfaction of Men and Partners Following Switch from On-Demand Phosphodiesterase Type 5 Inhibitor Therapy to Tadalafil 5 mg Once Daily
    Burns, Patrick R.
    Rosen, Raymond C.
    Dunn, Marian
    Baygani, Simin K.
    Perelman, Michael A.
    JOURNAL OF SEXUAL MEDICINE, 2015, 12 (03) : 720 - 727
  • [3] A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis
    Sugimoto, Mikio
    Zhang, Xia
    Ueda, Nobufumi
    Tsunemori, Hiroyuki
    Taoka, Rikiya
    Hayashida, Yusi
    Hirama, Hiromi
    Miyauchi, Yasuyuki
    Matsuoka, Yuki
    Naito, Hirohito
    Osaki, Yu
    Kekehi, Yosiyuki
    BMC UROLOGY, 2019, 19 (01)
  • [4] EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor
    Okuyucu, Esra E.
    Guven, Oguz
    Duman, Taskin
    Gorur, Sadik
    Melek, Ismet M.
    Akcin, Soner
    Yilmazer, Serkan
    NEUROLOGICAL RESEARCH, 2009, 31 (03) : 313 - 315
  • [5] CHOOSING THE 5TH TYPE PHOSPHODIESTERASE INHIBITORS FOR TREATMENT THE PATIENTS WITH ERECTILE DYSFUNCTION AND CHRONIC PROSTATITIS
    Esilevskiy, Yu. M.
    Demidko, Yu. L.
    Feyev, D. N.
    Gazimiev, M. A.
    Bezrukov, E. A.
    Butnaru, D. V.
    Bayduvaliev, A. M.
    Myannik, S. A.
    Epifanova, M. V.
    Chalyy, M. E.
    Kharchilava, R. R.
    ARCHIV EUROMEDICA, 2014, 4 (01): : 18 - 23
  • [6] Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome
    Pineault, Kevin
    Ray, Shagnik
    Gabrielson, Andrew
    Herati, Amin S.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (02) : 391 - 397
  • [7] A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition
    Fusco, Ferdinando
    Razzoli, Elisa
    Imbimbo, Ciro
    Rossi, Andrea
    Verze, Paolo
    Mirone, Vincenzo
    BJU INTERNATIONAL, 2010, 105 (12) : 1634 - 1639
  • [8] Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications
    Bella, Anthony J.
    DeYoung, Ling X.
    al-Numi, Mussa
    Brock, Gerald B.
    EUROPEAN UROLOGY, 2007, 52 (04) : 990 - 1005
  • [9] Elucidation of Phosphodiesterase Type 5 Inhibitor Mechanism of Action
    Dmochowski, Roger R.
    JOURNAL OF UROLOGY, 2013, 190 (04) : 1161 - 1162
  • [10] Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction
    Paick, Jae-Seung
    Ahn, Tai Y.
    Choi, Hyung K.
    Chung, Woo-Sik
    Kim, Je J.
    Kim, Sae C.
    Kim, Sae W.
    Lee, Sung W.
    Min, Kweon S.
    Moon, Ki H.
    Park, Jong K.
    Park, Kwangsung
    Park, Nam C.
    Suh, Jun-Kyu
    Yang, Dae Y.
    Jung, Hyung-Gi
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (11) : 2672 - 2680
12345